Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Greenbrook Tms Inc GBNHF

Greenbrook TMS Inc. is a provider of Transcranial Magnetic Stimulation (TMS) therapy and Spravato (esketamine nasal spray) therapy in the United States for the treatment of depressive disorder (MDD) and other mental health disorders. TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation. Spravato is offered to treat... see more

OTCQB:GBNHF - Post Discussion

Greenbrook Tms Inc > Record Results
View:
Post by retiredcf on Mar 11, 2020 10:00am

Record Results

And unfortunate timing. GLTA

Greenbrook TMS Reports Record Fourth Quarter and Year End 2019 Financial Results

Greenbrook TMS Inc. (TSX: GTMS) (“Greenbrook” or the “Company”) today announced its fourth quarter (“Q4 2019”) and year-end 2019 (“Fiscal 2019) operational and financial results. All values in this press release are in United States dollars, unless otherwise stated. 

FOURTH QUARTER AND YEAR END 2019 FINANCIAL AND OPERATIONAL HIGHLIGHTS

  • Q4 2019 revenue increased by 77% to a record $12.5 million, up $5.4 million from the fourth quarter of fiscal 2018 (“Q4 2018”). 
  • Fiscal 2019 revenue increased by 68% to $35.7 million, up $14.4 million from the 2018 fiscal year-end (“Fiscal 2018”). 
  • Q4 2019 regional operating income increased by 36% to $1.9 million, up $0.5 million from Q4 2018(1)
  • Fiscal 2019 regional operating income increased by 54% to $4.3 million, up $1.5 million from Fiscal 2018(1)
  • Added 62 TMS Centers during Fiscal 2019, 55 of which are active TMS Centers, bringing our total to 121 TMS Centers as at the date of this press release. 
  • Completed the acquisition of Achieve TMS Centers, LLC and Achieve TMS Alaska, LLC (collectively, “Achieve TMS”), which, provides the Company with a national footprint of over 100 TMS Centers. The acquisition also provides a platform for further expansion in the western United States, which is enhanced by Achieve TMS’ excellent brand recognition, physician reputation and high visibility in the local TMS community.
Be the first to comment on this post